Abstract:Depression is one of the complications in patients with polycystic ovary syndrome (PCOS) that leads to considerable mental health. Accumulating evidence suggests that human gut microbiomes are associated with the progression of PCOS and depression. However, whether microbiota influences depression development in PCOS patients is still uncharacterized. In this study, we employed metagenomic sequencing and transcriptome sequencing (RNA-seq) to profile the composition of the fecal microbiota and gene expression of peripheral blood mononuclear cells in depressed women with PCOS (PCOS-DP, n = 27) in comparison to mentally healthy women with PCOS (PCOS, n = 18) and compared with healthy control (HC, n = 27) and patients with major depressive disorder (MDD, n = 29). Gut microbiota assessment revealed distinct patterns in the relative abundance in the PCOS-DP compared to HC, MDD, and PCOS groups. Several gut microbes exhibited uniquely and significantly higher abundance in the PCOS-DP compared to PCOS patients, inducing EC Ruminococcus torques, Coprococcus comes, Megasphaera elsdenii, Acidaminococcus intestini, and Barnesiella viscericola. Bacteroides eggerthii was a potential gut microbial biomarker for the PCOS-DP. RNA-seq profiling identified that 35 and 37 genes were significantly elevated and downregulated in the PCOS-DP, respectively. The enhanced differential expressed genes (DEGs) in the PCOS-DP were enriched in pathways involved in signal transduction and endocrine and metabolic diseases, whereas several lipid metabolism pathways were downregulated. Intriguingly, genes correlated with the gut microbiota were found to be significantly enriched in pathways of neurodegenerative diseases and the immune system, suggesting that changes in the microbiota may have a systemic impact on the expression of neurodegenerative diseases and immune genes. Gut microbe-related DEGs of CREB3L3 and CCDC173 were possible molecular biomarkers and therapeutic targets of women with PCOS-DP. Our multi-omics data indicate shifts in the gut microbiome and host gene regulation in PCOS patients with depression, which is of possible etiological and diagnostic importance.

Deciphering the gut microbiota's (Coprococcus and Subdoligranulum) impact on depression: Network pharmacology and molecular dynamics simulation

Epigenetics in depression and gut-brain axis: A molecular crosstalk

Microbiota Alters and Its Correlation with Molecular Regulation Underlying Depression in PCOS Patients

Unveiling the Connection between Microbiota and Depressive Disorder through Machine Learning

Deciphering the Gut Microbiome's Influence on Depression: A Community-Level Constraint-Based Metabolic modelling Approach

Systems biology approaches to identify potential targets and inhibitors of the intestinal microbiota to treat depression

Depression-associated gut microbes, metabolites and clinical trials

The brain-gut-microbiota interplay in depression: A key to design innovative therapeutic approaches

Core Antibiotic Resistance Genes Mediate Gut Microbiota to Intervene in the Treatment of Major Depressive Disorder

Mechanistic Insights into the Link between Gut Dysbiosis and Major Depression: An Extensive Review

Effect of gut microbiome on serotonin metabolism: a personalized treatment approach

The Gut-Brain Axis and Its Role in Depression

Variations in Gut Microbiota and Fecal Metabolic Phenotype Associated with Depression by 16S Rrna Gene Sequencing and LC/MS-based Metabolomics.

Gut-to-brain axis provides novel therapeutic targets for depression

Potential role of gut microbiota in major depressive disorder: A review

Gut Microbiota Metabolites in Major Depressive Disorder—Deep Insights into Their Pathophysiological Role and Potential Translational Applications

Gut microbiota-derived short-chain fatty acids and depression: deep insight into biological mechanisms and potential applications

Mood and Microbes: a Comprehensive Review of Intestinal Microbiota’s Impact on Depression

The Gut Microbiota and Major Depressive Disorder: Current Understanding and Novel Therapeutic Strategies

Plant-derived bioactive components regulate gut microbiota to prevent depression and depressive-related neurodegenerative diseases: Focus on neurotransmitters

Multiomics Study of Gut Bacteria and Host Metabolism in Irritable Bowel Syndrome and Depression Patients